Heart failure & cardiomyopathies
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial
Authors' conclusion
A short course of danicamtiv was generally well tolerated in participants with DCM.
Study context
- Population
- Individuals with dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causes
- Participants
- 41 individuals
- Comparison
- Danicamtiv vs baseline
- MYH7n = 12
- TTNn = 14
- Other causesn = 15
- Outcome
- Safety/tolerability
Methodological detailsbaseline-controlled, in vitro assessments, Oral danicamtiv 25 mg twice daily in TP1 (1 week), adjusted in TP2 to 10 or 50 mg twice daily
- Baseline-controlled
- In vitro assessments
- Oral danicamtiv 25 mg twice daily in TP1 (1 week), adjusted in TP2 to 10 or 50 mg twice daily
Main finding
As reported in the abstract
Treatment-emergent adverse events
Treatment-emergent AEs (all mild or moderate)
22 (53.7%) of 41
Discontinuation
1
Secondary outcomes
| Outcome | MYH7 | TTN | Other causes |
|---|---|---|---|
| Change from baseline in LVEF · After TP2 | 8.8% (95% CI 5.03%–12.64%) | 5.9% (95% CI 2.59%–9.28%) | 4.4% (95% CI −0.90%–9.73%) |
Safety
- Asymptomatic increase in cardiac troponin — Other causes
- 3 events
Original publication
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial. J Am Coll Cardiol. Published 29 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →